Cytomegalovirus News and Research

RSS
Cytomegalovirus (CMV) is a member of the herpes virus group, which includes herpes simplex virus types 1 and 2, varicella-zoster virus (which causes chickenpox), and Epstein-Barr virus (which causes infectious mononucleosis). Infection with CMV is a major cause of disease and death in immunocompromised patients, including organ transplant recipients, patients undergoing hemodialysis, patients with cancer, patients receiving immunosuppressive drugs, and HIV-infected patients. While drugs are available for treatment of these conditions, the primary drug choices carry significant side effects and warnings. Currently, there are no anti-CMV drugs indicated for treatment of primary CMV infection during pregnancy resulting in infections that can have catastrophic consequences to the newborn. Maternal-fetal transfer of CMV infection results in a fetal death rate of 12% and most survivors have permanent debilitating disorders, including mental retardation, vision loss, and sensorineural deafness.

Further Reading

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Study opens the door to a new approach to attacking herpesviruses

Study opens the door to a new approach to attacking herpesviruses

Providing recombinant antibody services and more within Europe

Providing recombinant antibody services and more within Europe

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Transplant recipients benefit from a COVID-19 vaccine booster

Transplant recipients benefit from a COVID-19 vaccine booster

Cochlear implantation provides benefits for deaf children with autism spectrum disorder

Cochlear implantation provides benefits for deaf children with autism spectrum disorder

ACTG announces the launch of clinical trial to evaluate new CMV vaccine in adults

ACTG announces the launch of clinical trial to evaluate new CMV vaccine in adults

In-depth analysis of SARS-CoV-2 specific T cells in unexposed individuals

In-depth analysis of SARS-CoV-2 specific T cells in unexposed individuals

An antiviral regimen based on biomimetic polymers for COVID-19

An antiviral regimen based on biomimetic polymers for COVID-19

Cytomegalovirus herpesvirus can accelerate the decline of the immune system, study finds

Cytomegalovirus herpesvirus can accelerate the decline of the immune system, study finds

New evidence that SARS-CoV-2 virus can infect the inner ear

New evidence that SARS-CoV-2 virus can infect the inner ear

Study shows immune profile heterogeneity amongst healthy adults

Study shows immune profile heterogeneity amongst healthy adults

Novel Einstein-developed strategy successfully suppresses HIV infections in mice

Novel Einstein-developed strategy successfully suppresses HIV infections in mice

Research on twins indicates strong genetic influences in COVID-19

Research on twins indicates strong genetic influences in COVID-19

A new synthetic multiantigen MVA vaccine COH04S1 effective against SARS-CoV-2

A new synthetic multiantigen MVA vaccine COH04S1 effective against SARS-CoV-2

Saliva test to screen for leading infectious cause of infant hearing loss was feasible and well-received

Saliva test to screen for leading infectious cause of infant hearing loss was feasible and well-received

The tale of mRNA vaccines: Turning calamity into opportunity

The tale of mRNA vaccines: Turning calamity into opportunity

A systematic review of in vitro studies evaluating the efficacy of mouth rinses on SARS-CoV-2

A systematic review of in vitro studies evaluating the efficacy of mouth rinses on SARS-CoV-2

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus